DDInter75 DDInter1409
An antitubercular agent often administered in association with isoniazid. The sodium salt of the drug is better tolerated than the free acid.
Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021. Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS.
Aminosalicylic acid {u} (Compound) resembles {v} (Compound) Methyldopa
Methyldopa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Aminosalicylic acid {u} (Compound) resembles {v} (Compound) Levodopa
Levodopa {u} (Compound) resembles {v} (Compound) Methyldopa
Methyldopa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Aminosalicylic acid {u} (Compound) resembles {v} (Compound) Methyldopa
Methyldopa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naltrexone
Naltrexone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Aminosalicylic acid {u} (Compound) resembles {v} (Compound) Salicylic acid
Salicylic acid {u} (Compound) resembles {v} (Compound) Meclofenamic acid
Meclofenamic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Aminosalicylic acid {u} (Compound) resembles {v} (Compound) Levodopa
Levodopa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Aminosalicylic acid {u} (Compound) resembles {v} (Compound) Droxidopa
Droxidopa {u} (Compound) resembles {v} (Compound) Methyldopa
Methyldopa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Aminosalicylic acid {u} (Compound) resembles {v} (Compound) Levodopa
Levodopa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tocilizumab
Tocilizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Aminosalicylic acid {u} (Compound) resembles {v} (Compound) Methyldopa
Methyldopa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Brentuximab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Aminosalicylic acid {u} (Compound) resembles {v} (Compound) Diflunisal
Diflunisal {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Aminosalicylic acid {u} (Compound) binds {v} (Gene) ALOX5
ALOX5 {u} (Gene) is bound by {v} (Compound) Diclofenac
Diclofenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Aminosalicylic acid (Compound) resembles Methyldopa (Compound) and Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Aminosalicylic acid (Compound) resembles Levodopa (Compound) and Levodopa (Compound) resembles Methyldopa (Compound) and Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Aminosalicylic acid (Compound) resembles Methyldopa (Compound) and Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Aminosalicylic acid (Compound) resembles Salicylic acid (Compound) and Salicylic acid (Compound) resembles Meclofenamic acid (Compound) and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Aminosalicylic acid (Compound) resembles Levodopa (Compound) and Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Aminosalicylic acid (Compound) resembles Droxidopa (Compound) and Droxidopa (Compound) resembles Methyldopa (Compound) and Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Aminosalicylic acid (Compound) resembles Levodopa (Compound) and Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab and Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Aminosalicylic acid (Compound) resembles Methyldopa (Compound) and Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Aminosalicylic acid (Compound) resembles Diflunisal (Compound) and Diflunisal (Compound) resembles Flurbiprofen (Compound) and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Aminosalicylic acid (Compound) binds ALOX5 (Gene) and ALOX5 (Gene) is bound by Diclofenac (Compound) and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a